Press Releases
Bayer to present latest preclinical data on oncology compounds in 107th Annual Meeting of American Association for Cancer Research
Bayer will present latest preclinical data on oncology compounds, which are currently in preclinical or early clinical development stage at the American Association for Cancer Research (AACR) 107th Annual Meeting, April 16-20, 2016, in New Orleans, LA. ...
Press Releases
Kanuma receives marketing approval in Japan for Treatment of Patients with Lysosomal Acid Lipase Deficiency
Alexion Pharmaceuticals, Inc announced that Japan’s Ministry of Health, Labour and Welfare has approved Kanuma for the treatment of patients of all ages in Japan with lysosomal acid lipase deficiency. Kanuma, an innovative enzyme replacement therapy...
Press Releases
Phase 3 Study Findings Demonstrate Treatment With Baricitinib Results In Significant Improvements For Patients With Rheumatoid Arthritis Who Had Inadequate Response To Biologics
Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced that detailed results of RA-BEACON — a pivotal phase 3 global study of baricitinib, a once-daily oral treatment currently under regulatory review for the treatment of moderate-to-severe...
Press Releases
Proteostasis Therapeutics, Inc. Presents New Data Demonstrating Potential for Genotype-Agnostic and Combination Therapies for People with Cystic Fibrosis
Proteostasis Therapeutics, Inc. (NASDAQ: PTI), a biopharmaceutical company developing small molecule therapeutics to treat diseases caused by dysfunctional protein processing. such as cystic fibrosis (CF), today announced new preclinical data on the company’s first-in-class genotype-agnostic...
Press Releases
ASLAN Pharmaceuticals named Asian Biotech of the year
ASLAN Pharmaceuticals (ASLAN), a biotech company focused on the development of immunotherapies and targeted agents for Asia prevalent tumour types, has been named ‘Asian Biotech of the Year’. The award, presented this week at the 2016...
Press Releases
FDA Grants Genentech’s Cancer Immunotherapy Atezolizumab Priority Review for Advanced Bladder Cancer
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA) and granted Priority Review for atezolizumab (anti-PDL1. ...
Press Releases
Quintiles and the American College of Surgeons Announce Agreement to Develop Clinical Registry of the Future
Quintiles and the American College of Surgeons (ACS) today announced a six-year strategic services agreement to improve data collection and quality reporting for all ACS clinical registries. Working together, ACS and Quintiles will build a...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
















